RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.…
RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors
RenovoRx (NASDAQ: RNXT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 0.9420 USD on 20 November 2026, down 2.5% over 52 weeks. Its 52-week range is 0.7010 USD to 2.590 USD: the price is 63.6% below the high and 34.4% above the low.
Its market capitalisation is 45.45M USD.
RenovoRx reports return on equity of -206.0%, an operating margin of -467.4% and revenue up 300.8% year over year.
It holds more cash than debt, a net cash position of 10.05M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 8 March 2027.